Related Experiment Video
Updated: May 4, 2026

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
Published on: November 17, 2015
Evaluation of the properties of Gongronema latifolium in phospholipon 90H based solid lipid microparticles (SLMs): an
Salome Amarachi Chime1, Ikechukwu V Onyishi, Paschal U Ugwoke
11Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka, Nigeria.
Context:
Gongronema latifolium Benth Hook, (Asclepiadaceae) is a tropical rainforest plant primarily used in traditional folk medicine in the treatment of malaria, diabetes, hypertension, and as laxative.
Objective:
To study the antidiabetic properties of Gongronema latifolium-loaded solid lipid microparticles (SLMs).
Materials And Methods:
The methanolic extract of Gongronema latifolium leaves were obtained and formulated into SLMs using lipid matrix comprising of fat from Capra hircus and Phospholipon® 90H. The SLMs were characterized in vitro by determining the particle size and morphology, pH stability studies, and encapsulation efficiency EE%. Also, the antidiabetic properties of the Gongronema latifolium-loaded SLMs were studied in alloxan-induced diabetic rats.
Results And Discussion:
The results show that the particle size of G. latifolium-loaded SLMs was within an acceptable range for SLMs. Highest EE% of 68% was obtained for SLMs containing 5% G. latifolium (batch F3). The formulations remained stable with insignificant pH reduction over time (p < 0.05). Gongronema latifolium-loaded SLMs had mean percentage reduction in blood glucose of 76% at 2 h, 42.3% at 8 h, and 24.4% at 12 h, while the group that received the reference-glibenclamide had 82.6, 61.7, and 46.7% at 2, 8, and 12 h, respectively, after oral administration of all samples. Gongronema latifolium-loaded SLMs had blood glucose reduction significantly higher than the pure extract and the glibenclamide (p < 0.05) at the concentrations used.
Conclusions:
Gongronema latifolium-loaded SLMs exhibited a good hypoglycemic effect and could be used for the treatment of diabetes.
More Related Videos
Related Concept Videos
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

